$KIDS
OrthoPediatrics Corp

2024 Q3 Form 10-Q Financial Statement

#000142545024000079 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $54.57M $52.80M
YoY Change 36.53% 33.48%
Cost Of Revenue $14.51M $12.00M
YoY Change 60.92% 25.9%
Gross Profit $40.06M $40.80M
YoY Change 29.42% 35.88%
Gross Profit Margin 73.41% 77.27%
Selling, General & Admin $43.05M $43.92M
YoY Change 34.16% 33.83%
% of Gross Profit 107.46% 107.65%
Research & Development $2.577M $2.543M
YoY Change 7.96% -8.92%
% of Gross Profit 6.43% 6.23%
Depreciation & Amortization $5.280M $4.779M
YoY Change 23.65% 17.13%
% of Gross Profit 13.18% 11.71%
Operating Expenses $45.63M $46.47M
YoY Change 28.67% 30.48%
Operating Profit -$5.566M -$5.666M
YoY Change 23.47% 1.43%
Interest Expense -$404.0K -$261.0K
YoY Change 1920.0% -112.99%
% of Operating Profit
Other Income/Expense, Net -$3.571M -$381.0K
YoY Change -566.19% -231.83%
Pretax Income -$9.137M -$6.047M
YoY Change 144.17% 83.97%
Income Tax -$1.218M -$18.00K
% Of Pretax Income
Net Earnings -$7.919M -$6.029M
YoY Change 72.49% 108.91%
Net Earnings / Revenue -14.51% -11.42%
Basic Earnings Per Share -$0.34 -$0.26
Diluted Earnings Per Share -$0.34 -$0.26
COMMON SHARES
Basic Shares Outstanding 24.21M shares 23.83M shares
Diluted Shares Outstanding 23.17M shares 23.15M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.06M $28.93M
YoY Change -7.69% -68.96%
Cash & Equivalents $51.05M $28.93M
Short-Term Investments
Other Short-Term Assets $8.487M $6.462M
YoY Change 51.55% 23.37%
Inventory $120.9M $116.4M
Prepaid Expenses
Receivables $42.83M $42.03M
Other Receivables $0.00 $0.00
Total Short-Term Assets $248.3M $193.8M
YoY Change 9.79% -13.2%
LONG-TERM ASSETS
Property, Plant & Equipment $54.77M $53.48M
YoY Change 36.11% 33.47%
Goodwill $91.26M $90.51M
YoY Change 12.82% 9.17%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.26M $6.467M
YoY Change 1551.53% 953.26%
Total Long-Term Assets $241.0M $237.0M
YoY Change 16.83% 11.99%
TOTAL ASSETS
Total Short-Term Assets $248.3M $193.8M
Total Long-Term Assets $241.0M $237.0M
Total Assets $489.3M $430.8M
YoY Change 13.15% -0.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.65M $17.00M
YoY Change -48.43% -18.61%
Accrued Expenses $13.22M $12.62M
YoY Change 51.97% 54.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $624.0K $156.0K
YoY Change 212.0% 5.41%
Total Short-Term Liabilities $34.63M $39.57M
YoY Change -27.75% -10.7%
LONG-TERM LIABILITIES
Long-Term Debt $72.51M $9.782M
YoY Change 10259.14% 1321.8%
Other Long-Term Liabilities $4.799M $3.007M
YoY Change 761.58% -24.73%
Total Long-Term Liabilities $83.75M $19.90M
YoY Change 722.05% 324.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.63M $39.57M
Total Long-Term Liabilities $83.75M $19.90M
Total Liabilities $118.4M $59.47M
YoY Change 103.69% 9.0%
SHAREHOLDERS EQUITY
Retained Earnings -$219.5M -$211.6M
YoY Change 14.89% 13.47%
Common Stock $6.000K $6.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $370.9M $371.3M
YoY Change
Total Liabilities & Shareholders Equity $489.3M $430.8M
YoY Change 13.15% -0.94%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.919M -$6.029M
YoY Change 72.49% 108.91%
Depreciation, Depletion And Amortization $5.280M $4.779M
YoY Change 23.65% 17.13%
Cash From Operating Activities -$10.28M -$6.092M
YoY Change 18.56% 39.31%
INVESTING ACTIVITIES
Capital Expenditures $1.381M $6.684M
YoY Change -44.31% 18.87%
Acquisitions
YoY Change
Other Investing Activities -$25.39M $26.38M
YoY Change -308.95% -309.37%
Cash From Investing Activities -$26.77M $19.70M
YoY Change -376.81% -208.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 58.52M -4.269M
YoY Change -292690.0% 109.78%
NET CHANGE
Cash From Operating Activities -10.28M -6.092M
Cash From Investing Activities -26.77M 19.70M
Cash From Financing Activities 58.52M -4.269M
Net Change In Cash 21.47M 9.336M
YoY Change 2090.92% -137.9%
FREE CASH FLOW
Cash From Operating Activities -$10.28M -$6.092M
Capital Expenditures $1.381M $6.684M
Free Cash Flow -$11.66M -$12.78M
YoY Change 4.57% 27.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4739000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5483000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3007000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1112000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
19899000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
20054000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
59468000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
61720000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00025
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00025
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24216738 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97487000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71147000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17561000 usd
us-gaap Gross Profit
GrossProfit
72973000 usd
us-gaap Gross Profit
GrossProfit
53586000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
30762000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26082000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52059000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36269000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5541000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5412000 usd
us-gaap Operating Expenses
OperatingExpenses
88362000 usd
us-gaap Operating Expenses
OperatingExpenses
67763000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15389000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14177000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-2974000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-96000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
620000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-994000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3510000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16383000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10667000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2549000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-975000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13834000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9692000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22704723 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22704723 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22587022 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
610000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-118000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-301000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4698000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2511000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18532000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12203000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11309000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24514000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
378648000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6806000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-646000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Net Income Loss
NetIncomeLoss
-13834000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9692000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1858000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4689000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2820000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-7000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
109000 usd
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3263000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-2974000 usd
CY2024Q2 kids Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent
BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent
2371000 usd
CY2023Q4 kids Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent
BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent
3551000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23378408 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
593087000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
580287000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211576000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197742000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10224000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
371293000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
377025000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
430761000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
438745000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52802000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39559000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6029000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://www.orthopediatrics.com/20240630#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2024Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://www.orthopediatrics.com/20240630#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2024Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12003000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9534000 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
40799000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
30025000 usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16593000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13533000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27329000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19112000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2543000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2966000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
46465000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
35611000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5666000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5586000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
261000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
294000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
898000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
84000 usd
CY2024Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-2304000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
289000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-381000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2299000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6047000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3287000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-18000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-401000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6029000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2886000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23145064 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23145064 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22982921 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22982921 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22587022 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2886000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3263000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1865000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9292000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4751000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
377025000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7805000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1435000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2799000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
370584000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6029000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3263000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
2939000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
371293000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1959000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
373155000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2886000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1865000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3456000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
380312000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13834000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9692000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9807000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7928000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5738000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5415000 usd
kids Business Combination Contingent Consideration Change In Fair Value Accretion Of Acquisition Installment Payable
BusinessCombinationContingentConsiderationChangeInFairValueAccretionOfAcquisitionInstallmentPayable
537000 usd
kids Business Combination Contingent Consideration Change In Fair Value Accretion Of Acquisition Installment Payable
BusinessCombinationContingentConsiderationChangeInFairValueAccretionOfAcquisitionInstallmentPayable
812000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2955000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-975000 usd
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
4583000 usd
us-gaap Increase Decrease In Accounts And Notes Receivable
IncreaseDecreaseInAccountsAndNotesReceivable
8964000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10420000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11860000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
403000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-72000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4150000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9724000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
959000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1325000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1778000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1645000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12782000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10834000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
20693000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Business Two Net Of Cash Acquired
PaymentsToAcquireBusinessTwoNetOfCashAcquired
3097000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
49855000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
72347000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
44600000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13144000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10563000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16018000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14087000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
928000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
343000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
71000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
71000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4842000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2071000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-531000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-335000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2137000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
847000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33027000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10462000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30890000 usd
us-gaap Interest Paid Net
InterestPaidNet
760000 usd
us-gaap Interest Paid Net
InterestPaidNet
11000 usd
kids Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
281000 usd
kids Transfer Of Property And Equipment To Inventory
TransferOfPropertyAndEquipmentToInventory
367000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
293000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
67000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
us-gaap Nature Of Operations
NatureOfOperations
BUSINESS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spine, BandLoc Duo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Pediatric Nailing Platform | Femur, Devise Rail, Orthex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, The Fassier-Duval Telescopic Intramedullary System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SLIM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nail, The GAP Nail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, The Free Gliding SCFE Screw System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GIRO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Growth Modulation System, PNP Tibia System, ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mid-C System and Mitchell Ponseti</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation while our orthopedic bracing products are manufactured in-house plus clinical services. </span></div>We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis, sports medicine and specialty bracing and clinical services product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants, instruments and specialized braces to meet the needs of pediatric surgeons or orthotists and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market.
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-211576000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197742000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div>In the condensed consolidated financial statements, the Company has reclassified stock-based compensation to conform to the current period presentation. All stock-based compensation was previously recorded within general and administrative expenses, and such costs have now been allocated between general and administrative expenses, research and development expenses and sales and marketing expenses. The current presentation results in stock-based compensation expense being recorded in the same manner in which the award recipient's payroll costs are classified. This reclassification did not affect previously reported total operating expenses, loss before income taxes, or net loss in the condensed consolidated statements of operations.
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13533000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26082000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19112000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36269000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2966000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5412000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Concentration of Credit Risk </span></div>Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds.
CY2024Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
52802000 usd
CY2023Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
45837000 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
97918000 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
84272000 usd
CY2024Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-6029000 usd
CY2023Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-2770000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-13809000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-9460000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
83699000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
9217000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-2404000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
90512000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
93382000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25534000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
67848000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
91267000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21992000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
69275000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
11217000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
11063000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1279000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1003000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
156000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
152000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9782000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9908000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
156000 usd
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
421000 usd
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
11000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
760000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
22000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2549000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-975000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.156
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.091
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6029000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2886000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13834000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9692000 usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23145064 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23145064 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22704723 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22704723 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22982921 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22982921 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22587022 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22587022 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52802000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39559000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97487000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71147000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52802000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39559000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97487000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71147000 usd
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4162000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4539000 usd
CY2024Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
1092000 usd
CY2024Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
1456000 usd
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001425450-24-000079-index-headers.html Edgar Link pending
0001425450-24-000079-index.html Edgar Link pending
0001425450-24-000079.txt Edgar Link pending
0001425450-24-000079-xbrl.zip Edgar Link pending
exhibit311-ceocertificatio.htm Edgar Link pending
exhibit312-cfocertificatio.htm Edgar Link pending
exhibit321-ceocertificatio.htm Edgar Link pending
exhibit322-cfocertificatio.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kids-20240630.htm Edgar Link pending
kids-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
kids-20240630_cal.xml Edgar Link unprocessable
kids-20240630_lab.xml Edgar Link unprocessable
kids-20240630_pre.xml Edgar Link unprocessable
kids-20240630_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kids-20240630_def.xml Edgar Link unprocessable